NFE2L2 and cancer: Similarly, several clinical studies done in patients with other cancer types (melanoma, prostate, colorectal and renal carcinomas) have demonstrated that the intervention by small molecules or phytochemicals, such as glucoraphanin and bardoxolone methyl, are able to activate NRF2 signaling, suppressing the risk of cancer progression [88,89].